I'm 100% for unblinding too. Anyone who's looked at what evidence we do have knows our mortality rate is superior. That alone should give us an EUA regardless of p value. When push comes to shove we need to stop toadying up to the FDA and shove instead. If inferior drugs like lenzilumab hit the market first it will be an uphill battle to get into the marketplace and both patients and shareholders will suffer.